Virginia Commonwealth University

VCU Scholars Compass
Auctus: The Journal of Undergraduate Research and Creative Scholarship

2019

Pharmaceutical Industry's Effect on
Socioeconomic Development in Sub-Saharan
Africa in Relation to Family Planning Accessibility
Tessa Demarest
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/auctus
Part of the African Studies Commons, Medicine and Health Commons, and the Pharmacy and
Pharmaceutical Sciences Commons
© The Author(s)

Downloaded from
https://scholarscompass.vcu.edu/auctus/71

This Social Sciences is brought to you for free and open access by VCU Scholars Compass. It has been accepted for inclusion in Auctus: The Journal of
Undergraduate Research and Creative Scholarship by an authorized administrator of VCU Scholars Compass. For more information, please contact
libcompass@vcu.edu.

Running header: PHARMACEUTICAL INDUSTRY’S EFFECT ON AFRICA
1

Pharmaceutical industry’s effect on socioeconomic development in sub-Saharan Africa in
relation to family planning accessibility

Tessa Demarest
Virginia Commonwealth University

Author’s Note
Tessa Demarest is a student in the Honors College at Virginia Commonwealth University.
She was advised by Professor Faye Prichard and her classmates. This paper is her final project
for the class HONR 200, Rhetoric.
Correspondence concerning this article should be addressed to Tessa Demarest, VCU Honors
College, Virginia Commonwealth University
Contact: demarestte@vcu.edu

PHARMACEUTICAL INDUSTRY’S EFFECT ON AFRICA
DEMAREST
Abstract
There is a large unmet need for family planning services in sub-Saharan Africa
(Goodkind et al, 2018). Pharmaceutical companies contribute to the accessibility of medications
in developing countries (Cottingham & Berer, 2011). If the pharmaceutical industry strongly
affects access to contraceptives in sub-Saharan Africa, then it is possible that adjustments made
to the industry would increase access to contraceptives.
I explored how contraceptives change the economic and social development of subSaharan Africa to determine if contraception benefits Africans enough for their shortage to be a
serious injustice. This is followed by how the pharmaceutical industry affects access to and types
of birth control available in the area. The potential solution of instilling more non-profit medical
institutions to increase contraceptive availability is also probed.
It was concluded that access to reproductive health services in sub-Saharan Africa should
be available due to their overwhelmingly positive economic and social benefits. However, the
for-profit pharmaceutical industry creates obstacles for universal access, such as intellectual
property rights and a profit-motivated model (Cottingham & Berer, 2011). Though a nonprofit
pharmaceutical system and alternative medications may increase availability of reproductive
health services, more research should be conducted as to how a more socialized form of
medicine would increase universal access to contraceptives.
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Pharmaceutical Industry’s Effect on Social and Economic Development in Sub-Saharan Africa
in Relation to Family Planning Accessibility

Katz (2015) wrote an essay containing the following interviews:
Last month, Stembile Mugore visited a hospital in Togo, where she met a 24-year-old
woman who had just given birth to her fifth child. Mugore is an advisor to Evidence to
Action, USAID’s global flagship for strengthening family planning, and she had come to
Togo to follow up with a group of midwives who had been trained by USAID. The new
mother’s labor had been difficult, and she did not want to become pregnant again in the
near future. But she also had no idea how to prevent it from happening.
“She didn’t know anything about family planning,” Mugore recalled. “She’d
never heard [of it]. She’d had these babies very closely spaced.” After discussing her
options with a hospital midwife, the woman decided to receive an implant — a small,
rod-shaped form of birth control that is inserted into the arm, and that lasts for up to three
years.
“I remember very well the smile and the satisfaction on her face after she’d had
this implant,” Mugore said. “And how she wished she had known [about it sooner].”
(para. 1-3)
In the same Katz (2015) essay, “Why 222 Million Women Can’t Get the Birth Control
They Need”, Upadhyay, the Head of Reproductive Health Commodity Security and Family
Planning at the United Nations Population Fund, proclaims:
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“Family planning, it’s a human rights issue. It’s a prevention issue. It’s a women’s
issue… How many women will have an unplanned pregnancy, and how many women
will die because of that? [There] should be a movement all over the world.” (para. 15)
In some parts of the world, a woman cannot decide whether or not she has a child.
Cottingham and Berer (2011) say between 700 and 800 million women and couples use
contraceptives, while 215 million women who desire it are unable to obtain birth control. In the
United States, conservative ideologies, financial inequalities, and other barriers to public health
have prevented family planning services from reaching people in need. However, changing
beliefs have led to a new movement, one which advocates for more women to be able to access
reproductive and sexual health care. Though the current presidential administration plans to
decrease funding for contraceptives, and is less supportive of socialized medicine than the
previous administration, the United States population still has better access to family planning
services than many other countries.
The countries of sub-Saharan Africa have a high rate of unmet need for contraceptives.
(Goodkind et al., 2018). In an article by the Population Division of the U.S. Census Bureau,
Goodkind, Lollock, Choi, McDevitt, and West (2018) show that of the 13 countries the United
Nations projected to have the lowest met need for contraceptives, eight were countries in subSaharan Africa. Humanitarian aid from the United States government as well as international
nonprofits goes to sub-Saharan Africa in the form of food, water, shelter, medicine, and more.
However, while some aid is provided, universal access to family planning is still far from a
reality. In the country of Southern Sudan, the demand for contraceptives which was met with
modern contraceptive methods was only 6.1% in 2014, compared to 52.1% in the Philippines
that same year (Figure 2).
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The examination of how a lack of access to and types of birth control available in subSaharan Africa has changed the social and economic development of that area in important in
understanding the seriousness of this issue. Goodkind et al. looks at how the rate of met demand
defined as “percent of demand for family planning satisfied with modern contraception” (p. 1)
affects socioeconomic development. There are multiple possible justifications for sub-Saharan
Africa’s low rate of met need for contraceptives, including; social stigmas, a lack of knowledge
on contraceptives, financial limitations, and regional or landscape boundaries. Regardless of the
cause, the lack of these goods and services may lead to hardships for women. A woman without
effective contraceptives may have an unplanned, unwanted pregnancy, which can lead to the
birth of a child she does not have the means to support. On the contrary, access and use of
contraceptives positively correlate with the sexual empowerment of women, the likelihood of a
woman joining the labor force, and the chance that a woman’s child or children will attend
school (Crissman et al., 2012; Goodkind et al., 2018; Longwe & Smits, 2013).
However, there is adversity pertaining to increased access to family planning. Hynie and
Lydon (1996) suggest that a high positive sexual attitude, which is positively correlated with the
sex education that family planning programs may offer, can promote unsafe sex. This increases
the chance of STI transmission and unwanted pregnancy. According to Obianuju Ekeocha on
BBC World News, who is a pro-life advocate from Nigeria, believes Western involvement in
Africa’s reproductive and sexual health care is a form of ideological colonization of women who
do not desire birth control. With many differing opinions on increased access and use of family
planning in Africa, an in-depth examination of contraceptives’ socioeconomic influence is
necessary to decide if a lack of access is a serious problem.
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With almost infinite possible barriers to universal access to family planning, creating a
concise, informed answer for why there is a large unmet need for contraception is nearly
impossible. For that reason, this article examines the root of medication and vaccines: the
pharmaceutical industry. The pharmaceutical industry is responsible for the invention,
production, and distribution of medications and vaccines. In the United States, large
pharmaceutical companies are paid by the government, individual consumers, and nonprofits for
their products. In Africa, pharmaceuticals are also administered by the public sector, the private
sector, and the nonprofit sector (Tumlinson et al., 2011). For my research, I examined how forprofit pharmaceutical companies affect women and families’ access to reproductive health
services, as well as how it alters the types of reproductive goods and services available. There
are many laws and policies surrounding the pharmaceutical industry, such as those preventing
unethical drug trials (Moon, 2012). United Nation guidelines pressure ethical business practices
within the pharmaceutical industry (Moon, 2012). Nevertheless, products are still largely
unavailable from economic failures. Due to a lack of success in access to contraceptives, this
article concludes with the possibility that a larger prevalence in nonprofit pharmaceutical
suppliers or public pharmaceutical suppliers may increase access to family planning products and
services.
Due to overwhelming positive economic and social development created by family
planning goods and services, sexual and reproductive health services in sub-Saharan Africa
should be made more accessible. However, the for-profit pharmaceutical industry creates
obstacles for universal access, such as intellectual property rights and a desire to make a financial
profit. This research aims to come closer to a solution for how women who desire family
planning can receive it, regardless of social or economic status.
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Social and Economic Effects
Pharmaceuticals can decrease mortality, improve health, and increase social and
economic development. This section studies the social and economic effects of contraceptives in
sub-Saharan Africa. In particular, it discusses the demographic population shift, the sexual
empowerment of women, increased educational opportunities, and possible negative effects of
increased family planning.
Goodkind, Lollock, Choi, McDevitt, and West (2018) claim that increasing the rate of
met demand for family planning would alter the demographics of 13 tested countries, providing
positive effects for these countries. Goodkind et al. defines the term met demand as “percent of
demand for family planning satisfied with modern contraception” (p. 1). The selected countries
were 13 that the United Nations projected as being the furthest away from the benchmark of 75%
met demand.
The first step in the study by Goodkind et al. was translating contraceptive use into
probable fertility rates of the 13 selected countries. The study used the equation:
TFR = [Cm*Cc*Ci*Ca*Cp*TF]
TFR stands for the number of expected births per woman. This is meant to result from the
multiplication of several different factors, including the proportion of women aged 15- 49 who
are married (Cm), the index of contraception (Cc), the index of postpartum insusceptibility (Ci),
the index of abortion (Ca), an index of infecundity or pathological sterility (Cp), and total
fecundity (TF), which was estimated at roughly 15 births per woman. Data from the Census
Bureau (2014) was used, as well as projected data for 2030 to come up with the projected
increase of the modern contraceptive prevalence rate (MCPR). Goodkind et al. (2018) uses these
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differing rates to start the second step: “incorporating fertility estimates in cohort component
population projections” (p. 4).
Using this equation and data, Goodkind et al. (2018) were able to predict the population
size and ages if the 75% benchmark met demand for contraceptives was obtained by 2030.
This study found that a higher met demand would cause a slower population growth. This
in turn would shift the countries’ demographics, including a lower percentage of children, and a
higher percentage working-age individuals. A decrease of dependent youth (children who need
to be taken care of) and an increase of economically productive people (people who can work
and hold jobs) allows for more men and women to enter the labor force. Goodkind et al. (2018)
infers this would make it easier for developing countries to provide sustainable infrastructure and
increase economic development.
Goodkind et al.’s study illuminates the positive economic development from met family
planning needs. Research by Crissman, Adanu, and Harlow (2012) studies the positive social
aspects of contraceptives.
Crissman, Adanu, and Harlow (2012) hypothesize that a lack of sexual empowerment
among women imposes a barrier on their access to family planning methods and reproductive
health. It defines women sexual empowerment as a woman’s “perception of the right to selfdetermination in sexual relations” as well as the right to make sexual decisions (p. 202). Through
using the 2008 Ghana Demographic Health Survey, the authors found that increased sexual
empowerment of women is correlated with an increase in the use of birth control. Crissman,
Adanu, and Harlow conclude that the issue of sexual empowerment, especially among lowincome women, should be further researched and addressed in order to achieve universal access
to reproductive health services.
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Those selected for the study were randomly selected from 412 geographic clusters within
Ghana’s 10 geographical regions, and 4,917 out of 5,094 eligible women completed the survey.
Out of the 4,917 women, 2,104 identified as being married, not pregnant, not wanting to get
pregnant soon/within the next three months, and not missing key components for the analysis.
Out of that sample, 589 women were using contraceptives while 1,515 were not. The women for
the Crissman et al. (2012) study were given a questionnaire consisting of the following
questions:
● Can you say “no” to your husband/partner if you do not want to have sexual intercourse?
● In your opinion, is a husband justified in hitting or beating his wife if she refuses to have
sex with him?
● Could you ask your husband/partner to use a condom if you wanted him to?
● If a wife knows her husband has a disease that she can contract during sexual intercourse,
is she justified in asking him to use a condom when they have sex?
● Is a woman justified in refusing sex if she is tired/not in the mood? (p. 203)
The results found that sexual empowerment is different from other forms of
empowerment, such as empowerment found through wealth and education, though these forms
of empowerment are positively correlated. A major factor which was discovered in result of this
survey was the religious connections in Ghana to birth control use. For example, Muslim women
were much less likely to use contraceptive methods than Christian women. There is a higher
concentration of Muslim women in Northern Ghana, so this data could be slightly related to a
lack of access in Northern Ghana. However, after controlling for demographic differences, use is
still statistically lower in Muslim women.
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This study by Crissman et al. (2012) displays how a Ghanaian woman’s level of sexual
empowerment is associated with contraceptive use. The debate exists as to whether contraceptive
use increases sexual empowerment, or if a higher level of sexual empowerment increases a
woman’s likelihood to use contraceptives. It could possibly be both: having control over the
spacing and number of their children can be empowering, while being empowered may cause
one to want to have power over the spacing and number of their children. Either way, this type of
empowerment offers a solution to increase contraceptive use without pushing ideologies onto
Ghanaian women.
On the contrary, evidence shows heightened sexual empowerment in women may
decrease their use of birth control. Hynie and Lydon’s (1996) article discusses the possible low
use of birth control in women with a positive sexual attitude. This differs from the previous
viewpoint that women with a negative sexual attitude are less likely to use birth control.
Hynie and Lydon (1996) based their study on two hypotheses. First, that there would be a
quadratic relationship between the Sexual Opinion Survey (SOS), a survey commonly used to
project sexual attitude, and contraceptive behavior. This means that women with negative sexual
attitudes would be poorer contraceptive users, but also that women with an extremely positive
sexual attitude would be poorer contraceptive users than women with fairly positive sexual
attitudes. Second, that women would be more likely to report effective contraceptive behavior in
global behavior measure rather than measured by a daily diary. Global measurement is predicting
the contraceptive methods they would use in the upcoming week, while diary entries were
written after each intercourse session to establish what method of contraception was used.
The study included 62 women who were sexually active at least once in the five weeks
during the study. Women were asked to rank their contraceptive effectiveness 1-7, 1 being the
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most effective (a birth control pill with a condom) and 7 being the least effective (no
contraceptive used). Contraceptive consistency was also measured by calculating the percentage
of intercourse where a reliable method of birth control was used.
The study showed that women with very high SOS scores used significantly less effective
methods of contraceptives than women with moderate scores. Women with high SOS scores
were also less consistent in their contraceptive behaviors. There was a decrease in effective
contraceptive use from the first reported month and the methods predicted for next month. Also,
a bias was found in the global measures, with women documenting more effective contraceptive
use than what was actually performed. Finally, a quadratic relationship was found between
sexual attitude and contraceptive consistency, confirming the hypothesis.
However, high levels of arousal only interfered with contraceptives which were coitus
dependent, such as a condom. Methods such as the pill or an IUD were not interfered with
significantly in relation to a high positive sexual attitude. This study was also performed with
Canadian college students and adults. Since this article is related more to coitus independent
forms of contraception, and involves women in Sub-saharan Africa, it is not believed that this
study has a close enough relation for me to consider positive sexual attitude as a threat to
contraceptive use. Therefore, the hypothesis still stands that sexual empowerment should be
implemented into family planning practices in this area.
Educational opportunities and an educated population are important for social progress as
well as economic development. For this reason, it is important to understand the educational
effects of contraceptive use in sub-Saharan Africa.
Longwe and Smits’ (2013) article articulates the need for an increase in the knowledge of
contraceptives, as well as access to family planning practices in Africa. Their claims rest on how
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a lack of family planning continues the cycle of poverty – increasing fertility rates which reduce
women’s opportunities, as well as reduce the educational opportunities for their youth. They
claim that with contraceptives, educational opportunities are more available for both younger and
older children, because older children are able to go to school for longer if they do not have to
take care of their younger siblings. They also include that with fewer children, women have an
improved opportunity to enter the labor force. Through their data and findings, Longwe and
Smits want to convince policy makers that funding family planning education and practices will
be socially and economically rewarding.
Longwe and Smits’ (2013) evidence includes an analysis of family planning practices and
their outcomes on educational participation. The data includes both urban and regional areas of
233 subnational regions within 25 African countries. The study covers almost two decades; from
1992 to 2009. They used this data to answer three focus questions:
• What is the extent to which birth rates relate to primary school participation?
• What is the extent which birth rates relate to contraceptive use?
• What is the extent which contraceptive use is related to knowledge and acceptance of
contraceptives?
The article also contains a web diagram to illustrate how the data found correlates to each
other. Called “The Input Path Diagram of the Conceptual Model”, it states “Change in
acceptance of FP” (FP = family planning) comes first in the cause and effect chain, followed
consequently by “Change in contraceptive use”, “Change in number of recent births”, then
“Changes in primary school participation” (p. 25).
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The results showed that knowledge of contraceptives positively correlated with more
contraceptive use and acceptance. More contraceptive use showed a decrease in births, as well as
an increase in the number of eight to 12-year-olds attending school.

Pharmaceutical Industry Effects
The pharmaceutical industry can be viewed like any other for-profit industry: looking to
make a profit, they must create a desired product, and they must follow governmental and NGO
guidelines. However, unlike other businesses, pharmaceutical companies create products that are
necessary for people to survive and develop.
With the necessity of pharmaceuticals comes unique guidelines and restrictions. The
United Nations’ legislation surrounding pharmaceuticals as well as the industry’s for-profit
nature decreases access to generic medications, new medications, and vital medications in SubSaharan Africa (TRIPS, 1994). In an article by Cottingham and Berer (2011), they elaborate on
the claim that pharmaceutical companies are inhibiting the mass circulation of affordable family
planning products in developing countries. The authors call for more public investment in
essential medicine (which leads to increased access to generic, cheaper drugs) and strategic plans
which will increase medications and technologies universally available for specific ailments.
Cottingham and Berer (2011) have multiple claims for their reasoning. First,
pharmaceutical companies invest in products that will create a profit, which under-serves
disadvantaged communities, as well as ignores negative side effects of certain products. To help
improve quality of care, procedures and medications have been improved. These include safer
abortions (manual vacuum aspiration and medical abortion pills), safer female and male
sterilization and IUDs, new emergency contraceptives, oral pills that can be ingested less
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frequently, and new ways for hormones to be used and administered (p. 71). However, many
pharmaceutical companies lack interest in deploying these new methods in developing countries
because they lack profit when administered to people who would need to be charged a
considerably lower fee than their Western counterparts.
Legal issues regarding marketing new essential medicines at prices where many people in
developing countries would be able to pay for them is the second reason for the lack of access to
family planning and medications. The Essential Medicines Programme (EMP) developed by the
World Health Organization aims to help countries formulate national medicine policies, select
essential medicines, and set up structures that allow for their availability. Essentially, the EMP
hopes to create “affordability and rational use of good medicines that [are] safe, effective, and of
good quality” (Cottingham & Berer, 2011). However, the program conflicts with pharmaceutical
companies, primarily in the global battle for programs such as EMP to deploy generic,
antiretroviral medicines. While pharmaceutical companies want to keep their patents on the
drugs to sale more expensive name-brand drugs, both for-profit and nonprofit groups are trying
to develop generic versions of the medications that are less expensive for more people to afford
them, causing conflict between the two opposing sides.
Cottingham and Berer (2011) also reference the international patent system for
pharmaceuticals and how it limits universal access to family planning. The Trade-Related
Aspects of Intellectual Property Rights (TRIPS) grants a patent to the developer of a medicine
for 20 years. Installed to protect the rights of the inventor, it initiates a possible monopoly on that
medicine. A solution for some medications is compulsory licensing, where developing countries
are given permission by the government to use the patented products so they can sell the drugs at
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lower costs to those in need. Yet Western countries “presumably backed by the pharmaceutical
industry” are trying to enact stricter laws on compulsory licensing (p. 76).
The United Nations also recognizes pharmaceutical companies create a problem in
regards to universal access to medicine, and in turn has created legislation to try to combat the
issue. In her article discussing United Nations documentation surrounding the pharmaceutical
industry, Moon (2012) discusses the challenges of TRIPS and a for-profit market in the
pharmaceutical industry. However, Moon finds discrepancies in the work of the United Nations,
calling for the Framework Convention on Global Health to include private for-profit entities and
to create more regulations.
Moon addresses two United Nations mandates to educate the reader, then scrutinizes
what the documents fail to address. The first mandate of the two discussed by Moon is Paul
Hunt’s Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to
Medicines (2008), which instructs pharmaceutical companies on ethical practices. Hunt
elaborates on the idea that the practices of pharmaceutical companies may prevent states from
providing the best health care (p.18). Some examples he uses is how pricing, research, and
medical practices of the company may interfere with state practices, hurting public access to
medicine. Hunt declares that more state control of medicine is better than for-profit providers;
however, since that is not always the case, pharmaceutical companies have several social
responsibilities. This creates “right-to-health responsibilities”, such as how the patent holder to a
life-saving medicine should have the responsibility to disperse the medicine ethically (Moon,
2012).
The second mandate written from what Moon discusses is The UN Guiding Principles on
Business and Human Rights (2011) by John Ruggie, created to address issues surrounding
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business interference and human rights (the Ruggie Principles). The document cites respect as
the baseline expectation for businesses. This includes businesses cannot harm the public with
their practices, and that their own practices must come secondary to the actions of the state. The
document also includes specifics regarding pharmaceutical companies, such as requiring clinical
trials to be ethical and respectful of human rights and allowing countries to use compulsory
medicine for better access to medicine. The Ruggie Principles then discuss remedy, which claims
those who feel wronged by the company have the right to come forward with their issues and
receive remediation. It also views transparency as vital, calling for pharmaceutical companies to
make their objectives known to the public, as well as disclosing their lobbying actions and ties
with political parties, trade associations, and other key opinion leaders. However, Moon (2008)
believes that holding companies to these standards is unrealistic without binding state standards.
Both of these mandates believe businesses, including pharmaceutical companies, have
responsibilities to maintain as holders of patents for medicine and providers of necessary medical
procedures. They also believe separation from public medicine should not undermine desirable
donations and contributions from pharmaceutical companies, but it should come second to the
actions of the state. However, Moon (2008) believes there are still many discrepancies within
these mandates. For example, TRIPS can cause for large medicine monopolies that would inhibit
people from getting medications and vaccines, yet the documents do not account for these
complications. The documents also do not supply money for research for non-commercial
diseases. A symbiotic relationship between states and pharmaceutical companies is still unable to
be created. Through describing these declarations, Moon argues there needs to be more public
policy to insure pharmaceutical companies are acting with respect and ethics, as well as to help
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subsidize medicine for disadvantaged people. For these reasons, she asks for the Framework
Convention on Global Health to include private for-profit entities to create more regulations.
Moon (2008) believes more regulations need to be put on private pharmaceutical
suppliers to promote universal access to family planning. Moon, Hunt, and Ruggie also believe
state suppliers of pharmaceuticals are better for the overall development of areas receiving
donated or paid for private goods. However, the article fails to discuss nonprofit medical
systems.

Possibility of a Nonprofit Solution
A nonprofit organization runs on a similar business model as a for profit business; however,
profit generated by the nonprofit must be reinvested back into the organization’s mission, not to
stakeholders. Though there can still be corruption within a nonprofit, more money is meant to go
towards the beneficiaries of the organization, rather than the creators. For this reason, a nonprofit
medical system that contains nonprofit pharmaceutical providers may allow for the best universal
access to family planning. A major nonprofit family planning provider is the International
Planned Parenthood Federation.
The International Planned Parenthood Federation (IPPF) is an offshoot of the American
nonprofit, Planned Parenthood Federation of America. Claeys (2010) illuminates the positive
work of the IPPF in her article, using it to support sexual and reproductive health rights and the
NGO. She includes the European Region’s launch of the IPPF Charter on Sexual and
Reproductive Rights, creating international legislation in regards to sexual and reproductive
health. Its goal was to create a standard for judging sexual and reproductive health violations. In
2008, the IPPF published Sexual Rights: an IPPF Declaration, declaring reproductive rights as a
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human right. It is also mentioned that the United Nations, after urge from the IPPF, created a
resolution exclaiming it is a right for parents to “decide freely and responsibly on the number and
spacing of their children,” as well as to have “adequate education and information” (p. 73).
Claeys also supplies a large amount of statistics emphasizing the ability of the IPPF to be large
and all-encompassing, such as with national affiliates in Japan, South Korea, Bermuda, and
many more. She also includes after the International Conference on Population and Demand in
1994, chaired by the IPPF President at the time, that there was a need for “universal access to
reproductive health by 2015” (p. 71-72). This started the groundwork for Millennium
Development Goals in 2000, which worked to decrease maternal mortality rates and HIV/AIDS
prevention.
Though those accomplishments are successes in the fight for universal access to
contraceptives, Claeys (2010) briefly analyzes the counter arguments of promoting IPPF. This
includes cultural differences internationally (for example, a higher concern in Africa about being
infertile rather than pregnancy prevention) and the belief that ‘local people… provide the best
response to local needs’ (p. 70). However, Claeys combats these claims by playing on the
emotional and ethical appeals of her audience, proclaiming that “many governments... are still
not valuing women's’ lives” (p. 74) and that sexual right violations are continuing to occur due to
lack of proper protection by people and organizations.
With Claeys (2010) being an employee of IPPF, there are numerous biases and opinions
within the article. A person with the time and capabilities to write about an organization is likely
to have ties within the organization; however, Claeys’ includes how a major principle of the
IPPF is that the implementation of practices should come from demands within the country, and
that locals can provide better than outsiders. This counteracts the fact that as a business, their
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services will no longer be needed if local people have complete independence in relation to
healthcare. However, it is clear in many ways, such as less reliance on donors, that a community
having a successful, independent family planning system would be more beneficial than one
dependent on international NGOs.
Not only is birth control security increased without outsourced family planning, but
medical goods can also be provided for cheaper by the public sector. The concept that a state
may provide better medical treatment than private corporations reappears in an article covering
Sino-implant(II) by Tumlinson et al. (2011). Sino-implant(II) is a contraceptive implant which
closely resembles that of other contraceptive implants, yet costs about 60% less than other
implant methods (p. 88). This allows for states to pay for and provide this contraceptive without
relying as heavily on donors.
Kenya receives a significant amount of donated contraceptives, and could benefit from
less donor dependency and more birth control security. For this reason, Tumlinson et al. (2011)
addresses this new technology in conjunction with Kenya and it’s family planning system. The
authors discuss and analyze the idea that Sino-implant(II) could be a cost effective method for
Kenyan women in comparison to birth control pills, IUDs, and other methods; they also look at
the possibility that the cost of Sino-implant(II) could be self-sustaining in the public sector, forprofit sector, and not-for-profit sector.
The study included a sample size of 22 implant supplying facilities in Kenya. Eight of
these facilities were public institutions, six were private, for-profit institutions, and eight were
nonprofit institutions, affiliated with the International Planned Parenthood Federation. In the
study, 293 contraceptive implant users were interviewed, the interview containing questions
about why they choose the implant and how much the implant cost them (including the price of
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insertion and removal), and if they had been using the implant for six months or more. Out of the
293 implant users, 45% were from the public institutions,13% were from the private-for-profit
institutions, and 42% were from the private not-for-profit institutions. There was also an exit
survey for those leaving the facilities of about 412 participants, which were interviewed about
why they choose the method of birth control they did. It is important to note here that the
contraceptive implants used in this case study were not Sino-Implant(II), for this implant had not
been introduced into Kenya yet. However, similar implant products were used.
The studies and interviews conducted in 2007 outlined several findings. First, the selfreported median of prices for those with the implants from the public sector was US $1.30, from
the private for-profit sector was US $13.30, and US $20 in the private nonprofit sector. The
removal of the implants followed a similar pattern, with the cost being US $1.30 from public
sources, US $4.60 from private for-profit sources, and US $17.30 from the nonprofit sector. The
amount family planning donors were able to procure Sino-Implant(II) for was US $8.00,
allowing it to be cheaper than both the for-profit cost and not-for-profit cost of other implants.
This article offers a possible solution to medical cost recovery in Kenya. It also provides
evidence that a state-run system may offer cheaper contraceptives than private and nonprofit
companies. With a government medical system, sub-Saharan Africa could eliminate a private
medical system. This way, intensive government control may insure ethical practices. Also,
Sino-Implant(II) will not work for all women. Out of a sample of 412 women, only 6.5% of
women choose a contraceptive implant, with the main leading factor being the fear of side
effects, not excessive price. With a public system, alternate forms of contraceptives could be
offered at reduced rates.
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Negatives Effects of Contraception
Not all discussion on increased contraceptives in Africa is positive. The implementation
of increased contraceptive access must be performed in a way which does not undermine the
culture and beliefs of the people affected. However, it requires communication and compromise
from both sides for the benefits of contraception as well as the beliefs of the people who would
receive the healthcare improvements to be accepted. An example that illuminates the lack of
communication and compromise is a 2017 interview with Obianuju Ekeocha. A BBC Worldwide
News anchor interviewed pro-life activist Obianuju Ekeocha about her thoughts on access to
birth control in Africa. Ekecoha professes that she finds increased access to contraceptives
unnecessary, as well as a form of Western ideological colonization.
The BBC news anchor initiates the debate by claiming hundreds of millions of women do
not have access to contraception, claiming access to birth control is a universal right. Ekeocha
backfires, claiming that western groups offering abortion in Africa, an area where most people
do not support abortion, is a form of ideological colonization. Ekeocha claims, “Contraception
might be the tenth thing, if that…” on an African women’s list of needs and desires. She believes
instead women are asking for wood, food, water, and basic health care, so that should be the
focus of foreign aid. Ekeocha also combats contraception implementation because of a lack of
awareness towards their side effects.
The BBC interviewer suggests that contraceptive use can lead to the decrease of poverty,
suggesting that women having access to a family planning program helps improve other factors
in eliminating poverty. Speaking from experience as an African women who was able to get out
of poverty, Ekeocha claims an unmet need for contraceptives is not the single indicator of
poverty. In her own experience, education lead her out of poverty, and she believes Africans
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need education rather than contraceptives to combat poverty.

Conclusion
Ekeocha’s powerful interview straddled the viewpoints expressed in this article. While
other articles stated how contraceptives empower women and cause more Africans to go the
school, this video implies that contraception is demeaning African women and the focus of
nonprofit aide is being turned away from education. Ekeocha portrays contraceptives as
something most African women do not desire, and that it’s side effects are unknown and hurting
African women.
A point of weakness for this viewpoint is Ekeocha’s lack of sources for her answers.
None of the examples and statistics she gives are backed up with evidence or in studies. The
credibility of Ekeocha’s claims are more rooted in the fact that she herself is an African women
who was born and raised in Africa. However, Dr. Abiba Longwe-Ngwira, co-author of, “The
Impact of Family Planning on Primary School Enrollment in Sub-National Areas Within 25
African Countries”, is also an African woman, yet believes in improving the sub-Saharan access
to contraceptives (2013). Longwe-Ngwire’s research also illuminates an increase in youth
education opportunities when mothers use contraception.
But Ekeocha’s point that Western beliefs of what is good and necessary can differ from
African beliefs holds true. For example, Crissman, Adanu, and Harlow (2012) found that Muslim
women in Ghana were less likely to use contraceptives, likely due to their belief system. Though
contraception has many positive effects, the administration of medicine that is against one’s faith
would be a major injustice. For these reasons, while family planning should be equally accessible
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in the developing world as it is in developed countries, it should not be pressured on women who
do not desire modern contraceptives.
There is overwhelming evidence of improved socioeconomics in sub-Saharan Africa
through the implementation of contraception. These improvements are highly desirable, for they
can improve the lives of millions of children, women, and families. However, they should be
made accessible rather than forced, in order to not interfere with the beliefs of many African
people. With the current structure of pharmaceutical companies, universal access to family
planning is nearly impossible. However, by looking into more socialized medicine and the
empowerment of women, better access to contraceptives may be attainable.
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